Variable | Progression-free survival | Overall survival | ||
---|---|---|---|---|
 | Hazard ratio (95% CI) | Pvalue | Hazard ratio (95% CI) | Pvalue |
HR+ vs. HR- | 0.63 (0.46 to 0.86) | 0.003 | 0.51 (0.34 to 0.79) | 0.002 |
HER-2 amplified/overexpressed vs. HER-2 normal | 0.52 (0.34 to 0.79) | 0.002 | 0.39 (0.21 to 0.73) | 0.003 |
Visceral vs. other metastases | 1.39 (0.92 to 2.05) | 0.095 | 1.77 (0.95 to 3.30) | 0.074 |
Number of metastatic sites (1 vs. 3 vs. ≥ 3) | 0.88 (0.70 to 1.10) | 0.266 | 0.67 (0.47 to 0.95) | 0.024 |
Circulating tumor cells (< 5 versus ≥ 5) | 0.58 (0.43 to 0.79) | < 0.001 | 0.40 (0.26 to 0.62) | < 0.001 |